Table 1.

Characteristics of included studies and Jadad scores.

Study	Jadad	Intervention	n	Year	Study period	Efficacy index and Safety index
Wenfeng Fang (8)	6	Camrelizumab + gemcitabine + cisplatin vs Camrelizumab	23/93	18–70	12 months	ORR, PFS, adverse event rate (grade 1-5)
Jing Nie (17)	5	Camrelizumab+ Decitabine vs Camrelizumab	42/19	18–75	24 months	ORR, PFS, CR, adverse event rate (grade 1-5)
Jing Huang (18)	6	Camrelizumab vs docetaxel or irinotecan	228/220	18–75	24 months	ORR, PFS, CR, adverse event rate (grade 1-5)
Caicun Zhou (19)	6	Camrelizumab + Carboplatin + Pemetrexed vs Carboplatin + Pemetrexed	205/207	18–70	22 months	PFS, adverse event rate (grade 1-5)